All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Navigating FDA Regulatory Meetings

July 2, 2013
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2013
Volume 37
Issue 7

David Elder, vice-president, technical at PAREXEL, discusses the best way to productively participate in a regulatory meeting with FDA.

Q. How can my company participate productively in a regulatory meeting with FDA?

A. An invitation to a regulatory meeting with FDA might not be preferred, but it isn't entirely negative. FDA management initiates a regulatory meeting to inform responsible individuals about how one or more products, practices, processes, or other activities are considered to be in violation of the law (1). FDA views regulatory meetings as another tool to achieve prompt, voluntary compliance, typically initiated either to advise and educate prior to a warning letter or to provide additional assistance or direction after a warning letter. In the former example, FDA may use the regulatory meeting tool to deal with small firms, new firms, firms with a good history of compliance, or firms who make lower-risk products. In the latter example, FDA may use the regulatory meeting after a follow-up re-inspection found progress but lack of full compliance—the meeting would be another attempt to achieve or accelerate compliance before determining that it is necessary to initiate an enforcement action (e.g., injunction, seizure).

David Elder

There are some steps that should be taken to maximize one's chances of a productive and successful regulatory meeting.

Preparation

  • Know the issues at hand and FDA's concerns.

  • Prepare a slide deck that outlines corrective actions planned and accomplished. Include sufficient substance on the corrections, including metrics, timelines, and accountability.

  • Be sure to address systemic corrective actions, and not merely spot fixes, to potentially larger problems that could span multiple product lines or even multiple manufacturing locations.

  • Think of the specific areas of concern and the potential questions that could be asked. Address them proactively in the presentation or be prepared to address them fully during discussions.

  • Inform FDA who will be in attendance and request a list of likely FDA participants. The list of company participants should be limited but clearly must include executive management and other managers with knowledge, responsibility, and accountability for the issues at hand.

Meeting action

  • The highest-ranking company official is generally in charge of the company's actions at the meeting, opens the presentation, and directs questions to other company officials with the expertise needed to answer them.

  • All company officials in attendance must be fully knowledgeable of the issues and the company's corrective action plan to present information or answer questions during the meeting.

  • When answering questions, listen carefully and be certain you understand the question to ensure your answer is responsive.

  • If a question cannot be answered by any company official present, then promise to respond as soon as possible after the meeting with the required information.

  • At no point of the meeting should the company seek to make excuses or defend past actions or decisions. The meeting is about moving forward with complete, systemic corrective actions to achieve and sustain compliance.

  • Each company official must be 100% truthful always, without exception, caveat, or nuance.

Follow through

  • Any open questions from the meeting should be addressed promptly, and periodic updates should continue as decided during the meeting.

  • The company's meeting minutes should be shared with FDA to ensure full and mutual understanding of all concerns and commitments.

  • Executive management must ensure that all commitments made in the meeting are completed on the timetable promised and that the company achieves and sustains substantial compliance with all laws and regulations.

  • Upon FDA's re-inspection, it must be clear that systemic corrective actions have been completed, that they are effective, that all commitments have been supported, and that the company is operating in substantial compliance with the law and regulations. Failure to live up to commitments after a regulatory meeting is a recipe for enforcement action.

A company's measure for success for a regulatory meeting should actually be quite consistent with FDA's measure for success: a clear commitment to address all concerns and to achieve and sustain compliance with the law and regulations.

Reference

1. FDA, Regulatory Procedures Manual, Section 10-3, 2011, www.fda.gov/ICECI/compliancemanuals/regulatoryproceduresmanual/default.htm#_top, accessed June 17, 2013.

Articles in this issue

Regulatory Roundup
Evaluating Risk-Based Specifications for Pharmaceuticals
Evaluating Risk-Based Specifications for Pharmaceuticals
Controlling Drug Release Through Osmotic Systems
Controlling Drug Release Through Osmotic Systems
Q&A with Claudia Roth, President, Vetter Development Service, USA
Q&A with Claudia Roth, President, Vetter Development Service, USA
Report from Brazil July 2013
Report from Brazil July 2013
i4-817349-1408540310627.jpg
Editors' picks of pharmaceutical science & technology innovations
i4-817346-1408540316784.jpg
Evaluating Parenteral Packaging for Glass Delamination
i1-817357-1408540293854.jpg
Navigating FDA Regulatory Meetings
i1-817356-1408540295573.jpg
EU Battles Medicine Shortages
i1-817347-1408540314813.jpg
USP Partners Globally for 21st-Century Medicines
Gauging Investment in High-Potency Manufacturing
Gauging Investment in High-Potency Manufacturing
i1-817352-1408540304288.jpg
What Happened to Outsourcing in Asia?
i1-817353-1408540302050.jpg
FDA Urges Greater Focus on Contractor Quality
i1-817345-1408540319498.jpg
Extractables and Leachables: Best Practices to Ensure Patient Safety
Strengthening the Supply Chain for Pharmaceutical Ingredients
Strengthening the Supply Chain for Pharmaceutical Ingredients
Recent Videos
Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Related Content

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.